Trisenox
information and resources from the National Cancer Institute
NCI Thesaurus | Trisenox
(Other name for: arsenic trioxide)NCI Thesaurus | Trisenox
(Other name for: arsenic trioxide)
arsenic trioxide
Second line treatment of relapsed or refractory APL following ATRA plus an anthracycline.
Cell Therapeutic Sep 25 2000
|
|
|
|
news articles
Cell Therapeutics Reports Narrower Q4 Loss; Revenues Decline On ... Mar 9, 2006
Trading Markets, The quarterly results included $40.7 million gain on TRISENOX divestiture and a $23.6 million charge for the conversion senior subordinated notes. ...
Seattle biotech firm's drug marketing in question Mar 16, 2006
Seattle Post Intelligencer ...that prosecutors with the US Attorney's Office for Western Washington were looking at the company's handling of its only federally approved drug, Trisenox. ...
Cell Therapeutics discloses probe info Mar 17, 2006
Seattle Times, Cell Therapeutics first said last summer the US Attorney's Office was investigating its business practices related to Trisenox, a drug approved by the Food and ...
Cell Therapeutics, Inc. (CTI) Reports 2005 Fourth Quarter and Year ... Mar 9, 2006
MSN Money This included a $40.7 million gain in the quarter on the divestiture of TRISENOX(R) and a $23.6 million charge for the conversion of $38.4 million related to ...
Cell Therapeutics 4Q Loss Narrows Mar 9, 2006
MSN Money ...company focused on cancer drugs, on Thursday posted a smaller loss for the fourth quarter on a hefty gain from the sale of its leukemia treatment Trisenox. ...
Cephalon Granted Six Months of Pediatric Exclusivity for PROVIGIL Mar 28, 2006
PharmaLive.com (press release), ...in the United States: PROVIGIL, GABITRIL(R) (tiagabine hydrochloride) Tablets, ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], and TRISENOX(R) (arsenic ...
TABLE-Cell Therapeutics Q4 loss narrows Mar 9, 2006
Reuters ...--The biopharmaceutical company said the latest quarter included a gain of $40.7 million on the divestiture of Trisenox and a charge of $23.6 million for the ...
FDA Advisory Committee Recommends Against Approval of SPARLON(TM) ... Mar 23, 2006
Yahoo! News (press release) ...the United States: PROVIGIL, GABITRIL® (tiagabine hydrochloride) Tablets, ACTIQ® (oral transmucosal fentanyl citrate) [C-II], and TRISENOX® (arsenic trioxide ...
Earnings: Profit caps busy quarter for Cutter & Buck Mar 9, 2006
Seattle Post Intelligencer Cell Therapeutics recorded a $71.2 million gain for the year on its divestiture of the drug Trisenox. It is now focusing on Xyotax, an anti-cancer drug. ...
Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005
PR Newswire (press release), At ASH, researchers also will report data from investigator- sponsored studies of TRISENOX(R) (arsenic trioxide) injection, the company's marketed anti-cancer ...
Scientific Advances on Three Lead Cephalon Oncology Compounds to ... Dec 8, 2005
Yahoo! News (press release) At ASH, researchers also will report data from investigator- sponsored studies of TRISENOX® (arsenic trioxide) injection, the company's marketed anti-cancer ...
Cephalon Oncology Reports High Response Rates to Single Agent ... Dec 12, 2005
PR Newswire (press release), Cephalon Oncology Portfolio The Cephalon Oncology portfolio includes three lead compounds to treat patients with hematologic cancers: from TRISENOX(R) (arsenic ...
Cephalon Oncology Reports High Response Rates to Single Agent ... Dec 12, 2005
Yahoo! News (press release) The Cephalon Oncology portfolio includes three lead compounds to treat patients with hematologic cancers: from TRISENOX® (arsenic trioxide) injection, an ...
Cephalon to Webcast Dec. 19, 2005 Investor Meeting Dec 19, 2005
PharmaLive.com (press release), States: PROVIGIL(R) (modafinil) [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] and TRISENOX(R) (arsenic ...
Cephalon to Webcast Dec. 19, 2005 Investor Meeting Dec 16, 2005
Yahoo! News (press release) PROVIGIL® (modafinil) [C-IV], GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II] and TRISENOX® (arsenic trioxide ...
Cephalon Could Have A Tough Year In 2007 Dec 8, 2005
Forbes ...deal for Cephalon, as it will provide the company with a pan-European oncology franchise to complement its existing cancer product, Trisenox, and will give the ...
Cephalon expected to buy British drugmaker Dec 6, 2005
philly.com, ...$160 million. In June, Cephalon bought a marketed oncology product, Trisenox, from Cell Therapeutics Inc., Seattle. The acquisition ...
Cephalon, Inc. Announces Agreement with Teva Pharmaceutical ... Dec 9, 2005
PR Newswire (press release), ...products in the United States: PROVIGIL, GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] and TRISENOX(R) (arsenic ...
Cephalon, Inc. Announces Agreement with Teva Pharmaceutical ... Dec 9, 2005
Yahoo! News (press release) ...in the United States: PROVIGIL, GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal fentanyl citrate) [C-II] and TRISENOX® (arsenic trioxide ...
BMS' dasatinib expected to rival Gleevec Nov 21, 2005
Science Daily (press release) ...said, they will likely have a negative impact on the development of other CML medications, such as ChemGenex's Ceflatonin and Cell Therapeutics' Trisenox. ...
|
|
